Company: WHWK
Filing Date: 2025-05-08
Form Type: 10-Q
Source: 0001628280-25-023932
Chunk: 451

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-05-08
Form: 10-Q
Item: Part I, Item 8
Chunk 451
---
)Outstanding, December 31, 20244,950,016 $10.82 7.99$1,818 Granted687,979 2.31 Exercised(22,204)0.95 Cancelled/Forfeited(288,972)11.52 Outstanding as of March 31, 20255,326,819 $9.72 8.06$29 Options exercisable as of March 31, 20252,996,934 $13.26 7.41$— Vested and expected to vest as of March 31, 20255,326,819 $9.72 8.06$29 As of March 31, 2025, there was $8.4 million of unrecognized compensation cost related to stock options, which is expected to be recognized over a weighted average period of 1.92 years.The total intrinsic value of the options exercised during the three months ended March 31, 2025, and 2024, was $43,000 and $0, respectivelyAs of March 31, 2025, and December 31, 2024, 1,632,796 and 1,013,055 shares were reserved for future awards under the 2021 Plan, respectively. As of March 31, 2025 and December 31, 2024, 110,000 shares were reserved for future awards under the 2023 Inducement Plan.Restricted Stock UnitsRestricted stock consists of restricted stock unit awards (RSUs) which have been granted to employees. The value of an RSU award is based on the Company’s stock price on the date of grant. Employee grants vest over four years. Forfeitures 

19

of RSUs are recognized as they occur. The shares underlying the RSU awards are not issued until the RSUs vest. Upon vesting, each RSU converts into one share of the Company’s common stock.Activity with respect to the Company’s restricted stock units during the three months ended March 31, 2025 is as follows:SharesWeighted AverageGrant Date Fair ValueNonvested shares at December 31, 2024256,490 $1.92 Granted— — Vested/Issued(63,250)1.92 Forfeited(31,519)1.92 Nonvested shares at March 31, 2025161,